XLRN - Acceleron Pharma Plan For Sotatercept Adds To Buy Conviction October, 06 2020 06:19 PM Acceleron Pharma Inc. Acceleron will start a Phase 3 sotatercept for PAH trial by year end. Q3 results should show continuing good Reblozyl revenue ramp. It is possible sotatercept will see commercial sales in 2023 or earlier. For further details see: Acceleron Pharma Plan For Sotatercept Adds To Buy Conviction